Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche owing to the disease’s heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. However, with each new launch and growing generics competition, the market is becoming increasingly crowded. Meanwhile, early intervention with high-efficacy drugs continues to replace the escalation paradigm. Thus, players engaged in or entering this space must assess where their products, especially next-in-class alternatives, will fit. Our Treatment Algorithms study provides national patient-level claims data analysis, explores treatment progression by line of therapy, persistence and compliance by brand, and the positioning of current DMTs.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
- How has Briumvi been integrated into the treatment algorithm, and what is its source of business?
- What percentage of MS patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of MS patients are treated with monotherapy vs. combination therapy?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
Markets covered: United States
Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan / Viatris, Novartis, Sanofi, Teva, TG Therapeutics
Key drugs: Aubagio / teriflunomide, Bafiertam, Briumvi, Copaxone / glatiramer acetate, Gilenya / fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ocrevus Zunovo, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia
Key analysis provided
- Brand / therapy usage across patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flow.
